Tenax Therapeutics – Consensus Indicates Potential 191.3% Upside

Broker Ratings

Tenax Therapeutics found using ticker (TENX) now have 2 analysts in total covering the stock. The consensus rating is ‘None’. The target price ranges between 4 and 2 calculating the mean target price we have 3. With the stocks previous close at 1.03 this would imply there is a potential upside of 191.3%. The 50 day MA is 1.05 and the 200 moving average now moves to 1.21. The company has a market cap of $14m. Visit the company website at: http://www.tenaxthera.com

Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics and changed its name to Tenax Therapeutics in September 2014. Tenax Therapeutics was founded in 1967 and is headquartered in Morrisville, North Carolina.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp